Ophirex, Inc. is a biotech company structured around addressing major unmet needs in tropical medicine. With particular focus on development by the firm of program for the field treatment of envenomation - especially involving snakes - in August 2017 Ophitex licensed data related to sPLA2 inhibitors from Eli Lilly and Company and Shionogi, Inc. Since then, Ophirex, has developed a low-cost, snake-agnostic antidote with the effort being to test and manufacture the product in India where half the global snakebite deaths take place. Thoughout Asia - where 75% of snake bite deaths cccur - anti-venoms are available for different snakes, but deciding which one to use has been forever a problem especially when which snake had inflicted the wound was unknown. Ophirex's effort has been to address development of a single antidote to snakebites. Though the intent is to offer an IV version (hospital/military use) and also subcutaneous versions for veterinary use, unlike epipen, the firm's product can be taken orally.
